Sabrina Serani is a senior editor for Targeted Oncology.
Adagrasib/Pembrolizumab Promising in KRAS G12C-Mutated NSCLC
October 20th 2023Longer follow-up data from the KRYSTAL-7 trial support the initiation of a phase 3 trial evaluating concurrent adagrasib with pembrolizumab in treatment-naïve patients with KRASG12C-mutated non–small cell lung cancer and PD-L1 ≥50%.
Study Supports Daratumumab Use in R/R Multiple Myeloma
October 18th 2023While there was no significant difference in overall survival between the daratumumab and control groups, safety profile results and follow-up data support daratumumab’s continued evaluation in relapsed/refractory multiple myeloma.